Amyloid and Light Chain Deposition Disorders

Area of Science:

• Pulmonary Medicine
• Nephrology
• Pathology

Background:

• Amyloidosis and Light Chain Deposition Disease (LCDD) are systemic disorders characterized by abnormal protein deposition in various organs.
• Pulmonary involvement is a significant manifestation of amyloidosis, presenting diverse patterns like diffuse alveolar-septal, nodular, or cystic disease, and tracheobronchial issues.
• While LCDD primarily impacts the kidneys, it can also lead to pulmonary abnormalities, including cystic and nodular lung disease.

Purpose of the Study:

• To elucidate the diverse pulmonary manifestations of amyloidosis and LCDD.
• To differentiate the lung involvement patterns based on the specific type of amyloidosis (immunoglobulin light chain, serum amyloid A, transthyretin).
• To highlight the diagnostic approaches and therapeutic strategies for these protein deposition disorders affecting the lungs.

Main Methods:

• Review of existing literature on pulmonary amyloidosis and LCDD.
• Analysis of imaging findings (e.g., CT scans) associated with different types of amyloidosis and LCDD.
• Summary of diagnostic methods including tissue biopsy and laboratory tests.
• Overview of treatment modalities targeting underlying causes.

Main Results:

• Pulmonary amyloidosis presents with varied patterns: diffuse alveolar-septal, nodular, cystic, and tracheobronchial.
• Transthyretin amyloidosis (ATTR) is a rare cause of lung involvement.
• LCDD, though primarily renal, can manifest as cystic or nodular lung disease.
• Diagnosis relies on integrating clinical presentation, imaging, and histopathological examination.

Conclusions:

• Pulmonary involvement in amyloidosis and LCDD presents distinct radiological and pathological features.
• Accurate diagnosis through biopsy and imaging is crucial for appropriate management.
• Therapeutic strategies focus on addressing the underlying plasma cell dyscrasias or inflammatory conditions driving protein deposition.